NCT03053986

Brief Summary

Apple polyphenols are mostly acknowledged for their hypoglycaemic properties, but represent an apple active fraction with many pharmacological functions. The study aim was to examine their effect on uricemia and endothelial function in a sample of overweight subjects. This was a two-phases study. The in vitro experiment aimed to evaluate the apple polyphenols' ability to lower uric acid in comparison with allopurinol. The in vivo study consisted in a randomized, double-blind, parallel placebo-controlled clinical trial involving 62 overweight volunteers with suboptimal values of fasting plasma glucose (100 mg/dL≤FPG≤125 mg/dL), randomized to be treated with 300 mg apple polyphenols or placebo for 8 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 7, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 15, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2017

Completed
Last Updated

February 1, 2024

Status Verified

January 1, 2024

Enrollment Period

9 months

First QC Date

February 7, 2017

Last Update Submit

January 30, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Endothelial function

    Change in arterial diameter after ischemic stimulus

    8 week

Study Arms (2)

Apple polyphenols

ACTIVE COMPARATOR

White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)

Dietary Supplement: Apple polyphenols

Placebo

PLACEBO COMPARATOR

Indistinguishable capsules with similar dimension, colour, odour and taste

Other: Placebo

Interventions

Apple polyphenolsDIETARY_SUPPLEMENT

1 tablet per day at evening before sleeping

Apple polyphenols
PlaceboOTHER

1 tablet per day at evening before sleeping

Placebo

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body mass index (BMI)\>25 kg/m2
  • Fasting plasma glucose 100 mg/dL ≤ FPG ≤ 125 mg/dL

You may not qualify if:

  • Patients with obesity (body mass index \[BMI\] \<30 Kg/m2)
  • diabetes mellitus
  • personal history of atherosclerosis-related cardiovascular diseases (coronary artery disease
  • cerebrovascular disease
  • ultrasound diagnosed carotid atherosclerosis)
  • absorption disease
  • myopathy
  • renal failure or chronic liver disease
  • serious or invalidating other diseases reducing the subjects' ability to comply with the full protocol were excluded from the study as well as subjects with a known apple intolerance.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

S. Orsola-Malpighi University Hospital

Bologna, 40038, Italy

Location

Related Publications (1)

  • Cicero AFG, Caliceti C, Fogacci F, Giovannini M, Calabria D, Colletti A, Veronesi M, Roda A, Borghi C. Effect of apple polyphenols on vascular oxidative stress and endothelium function: a translational study. Mol Nutr Food Res. 2017 Nov;61(11). doi: 10.1002/mnfr.201700373. Epub 2017 Sep 1.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Full Professor of Internal Medicine

Study Record Dates

First Submitted

February 7, 2017

First Posted

February 15, 2017

Study Start

September 1, 2016

Primary Completion

June 1, 2017

Study Completion

June 1, 2017

Last Updated

February 1, 2024

Record last verified: 2024-01

Locations